



Vaccine Development for Influenza Virus

Guest Editors:

Prof. Dr. Mingtao Zeng

Center of Emphasis in Infectious Diseases, Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA

Dr. Ganesh Yadaigiri

College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA

Deadline for manuscript submissions:

30 September 2024

Message from the Guest Editors

Influenza viruses spread rapidly and can infect animals and humans. Vaccine development for animal and human influenza viruses is essential for protecting animal and human populations from seasonal flu strains and potential pandemics. In this Special Issue, we are interested in receiving a combination of original papers and reviews focusing on the following topics:

1. Immune responses to influenza virus infection and vaccination;
2. Challenges to current influenza vaccination strategies;
3. Innovative vaccine development technologies;
4. The application of nanotechnology in the delivery and formulation of vaccines.

Keywords: influenza vaccine; adjuvant; mRNA vaccine; novel vaccine technology; nanotechnology; immune response; animal; human





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com